1/16
10:40 am
syre
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
1/15
12:06 pm
syre
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]
Low
Report
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]
1/12
08:27 am
syre
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]
Medium
Report
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]
1/12
08:00 am
syre
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
Medium
Report
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
1/11
10:02 am
syre
Spyre Therapeutics' CEO Sells 15,000 Shares [Yahoo! Finance]
Medium
Report
Spyre Therapeutics' CEO Sells 15,000 Shares [Yahoo! Finance]
1/8
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Low
Report
Spyre Therapeutics Announces Grants of Inducement Awards
12/19
05:58 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
12/19
05:58 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Mizuho to a "strong-buy" rating.
12/17
07:01 pm
syre
Spyre Therapeutics (NASDAQ:SYRE) was given a new $53.00 price target on by analysts at Mizuho.
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was given a new $53.00 price target on by analysts at Mizuho.
12/17
07:06 am
syre
Spyre Therapeutics (NASDAQ:SYRE) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
12/5
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
12/1
08:35 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.
11/26
02:19 pm
syre
Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/17
01:42 pm
syre
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]
Low
Report
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]
11/16
01:08 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
11/9
07:03 pm
syre
Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? [Yahoo! Finance]
Low
Report
Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? [Yahoo! Finance]
11/7
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Low
Report
Spyre Therapeutics Announces Grants of Inducement Awards
11/4
04:05 pm
syre
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/4
04:01 pm
syre
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
Low
Report
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
10/29
04:05 pm
syre
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
Low
Report
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
10/24
08:00 am
syre
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Medium
Report
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025